A new classification for HIV-1

@article{Berger1998ANC,
  title={A new classification for HIV-1},
  author={Edward A Berger and Robert W. Doms and Eva Maria Fenyö and Bt Korber and Dan R. Littman and J. Peter Moore and Quentin J. Sattentau and Hanneke Schuitemaker and Joseph G. Sodroski and Robin A. Weiss},
  journal={Nature},
  year={1998},
  volume={391},
  pages={240-240}
}
The phenotype of HIV-1 isolates is defined by the cells in which they replicate in vitro, but these phenotypes can change in vivo with profound implications for viral transmission, pathogenesis and disease progression. Here we propose a new classification system based on co-receptor use, providing a more accurate description of viral phenotype than the present imprecise and often misleading classification schemes. 

The challenge of HIV-1 subtype diversity.

The implications of subtype diversity in HIV-1 for possible differential rates of disease progression, responses to antiretroviral therapy (including the development of resistance), and vaccine development are discussed.

Host genetic influences on HIV-1 pathogenesis.

  • N. Michael
  • Biology
    Current opinion in immunology
  • 1999

Clinical significance of HIV-1 coreceptor usage

This review summarizes the major findings on the clinical significance of the HIV-1 coreceptor usage and investigates the role of the viral phenotype in the variable clinical course and treatment outcome of HIV- 1 infection over the past two decades.

Genotypic tropism testing: evidence-based or leap of faith?

This work has identified a novel class of antiretroviral drugs that, uniquely among available agents, act on the host cell rather than the virus.

Coreceptor Usage and Biological Phenotypes of HIV-1 Isolates

A new class of drugs has emerged that are being tested to prevent virus infection and to act as an alternative, or adjunct, to existing anti-retroviral drugs for HIV-infected individuals.

Genotypic analysis of HIV-1 coreceptor usage

Anti-HIV drugs target essential viral proteins in the replication cycle of HIV, to date mostly the viral reverse transcriptase and protease, but the search for new targets is still necessary.

Biology of HIV-1 in women and men.

  • H. BurgerB. Weiser
  • Biology, Medicine
    Obstetrics and gynecology clinics of North America
  • 1997

Determination of HIV-1 co-receptor usage.

In this chapter, methods to determine the co-receptor usage of HIV-1 variants are described and phenotypically classified Viral isolates can be phenotypesically classified based on the co,receptor they utilize to infect target cells.

Point Mutations Associated with HIV-1 Drug Resistance, Evasion of the Immune Response and AIDS Pathogenesis

This research presents a probabilistic approach to estimating the response of the immune system to laser-spot assisted, 3D image analysis and shows promising results in terms of both accuracy and efficiency.

Chemokines and HIV-1 second receptors: The therapeutic connection

In this review, Scott Cairns and Patricia D'Souza discuss these potentially powerful approaches and how they complement existing antiretroviral drug therapy.
...

References

SHOWING 1-4 OF 4 REFERENCES

Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

It is shown that a mutant allele of CCR-5 is present at a high frequency in caucasian populations, but is absent in black populations from Western and Central Africa and Japanese populations, and a 32-base-pair deletion within the coding region results in a frame shift, and generates a non-functional receptor that does not support membrane fusion or infection by macrophage- and dual-tropic HIV-1 strains.

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1β, which is a CCR5 ligand that promotes efficient infection of the CNS by HIV- 1.